Teva Pharmaceutical Industries Stock Current Ratio
TEV Stock | 21.10 0.30 1.44% |
Teva Pharmaceutical Industries fundamentals help investors to digest information that contributes to Teva Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Teva Stock. The fundamental analysis module provides a way to measure Teva Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Teva Pharmaceutical stock.
Teva |
Teva Pharmaceutical Industries Company Current Ratio Analysis
Teva Pharmaceutical's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Competition |
In accordance with the recently published financial statements, Teva Pharmaceutical Industries has a Current Ratio of 0.0 times. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Current Ratio (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).
Did you try this?
Run Crypto Correlations Now
Crypto CorrelationsUse cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
All Next | Launch Module |
Teva Fundamentals
Current Valuation | 28.17 B | |||
Price To Book | 1.18 X | |||
Price To Sales | 0.68 X | |||
Revenue | 14.93 B | |||
EBITDA | (827 M) | |||
Net Income | (2.35 B) | |||
Total Debt | 19.1 B | |||
Cash Flow From Operations | 1.59 B | |||
Price To Earnings To Growth | 0.75 X | |||
Market Capitalization | 7.82 B | |||
Total Asset | 44.01 B | |||
Net Asset | 44.01 B |
About Teva Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Teva Pharmaceutical Industries's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Teva Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Teva Pharmaceutical Industries based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Teva Stock Analysis
When running Teva Pharmaceutical's price analysis, check to measure Teva Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharmaceutical is operating at the current time. Most of Teva Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Teva Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharmaceutical's price. Additionally, you may evaluate how the addition of Teva Pharmaceutical to your portfolios can decrease your overall portfolio volatility.